CN104039350B - 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导 - Google Patents
任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导 Download PDFInfo
- Publication number
- CN104039350B CN104039350B CN201280045106.2A CN201280045106A CN104039350B CN 104039350 B CN104039350 B CN 104039350B CN 201280045106 A CN201280045106 A CN 201280045106A CN 104039350 B CN104039350 B CN 104039350B
- Authority
- CN
- China
- Prior art keywords
- amino acid
- antibody
- polypeptide
- epitope
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 125000000539 amino acid group Chemical group 0.000 title claims abstract description 86
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 84
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 81
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 81
- 230000006698 induction Effects 0.000 title description 19
- 229960005486 vaccine Drugs 0.000 claims abstract description 17
- 108010067902 Peptide Library Proteins 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 5
- 229940023041 peptide vaccine Drugs 0.000 abstract description 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 101710200582 Major spike protein G Proteins 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 241001112090 Pseudovirus Species 0.000 description 24
- 238000006386 neutralization reaction Methods 0.000 description 22
- 238000001228 spectrum Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 230000003472 neutralizing effect Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000011587 new zealand white rabbit Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 5
- 238000001261 affinity purification Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000669 biting effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710114816 Gene 41 protein Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 108700008783 Hepatitis C virus E1 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 244000134336 Malus baccata Species 0.000 description 1
- 235000005079 Malus baccata Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535988P | 2011-09-17 | 2011-09-17 | |
| US61/535,988 | 2011-09-17 | ||
| PCT/US2012/055771 WO2013040564A2 (fr) | 2011-09-17 | 2012-09-17 | Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104039350A CN104039350A (zh) | 2014-09-10 |
| CN104039350B true CN104039350B (zh) | 2019-07-05 |
Family
ID=47884023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280045106.2A Expired - Fee Related CN104039350B (zh) | 2011-09-17 | 2012-09-17 | 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2755687A4 (fr) |
| JP (2) | JP2014527085A (fr) |
| CN (1) | CN104039350B (fr) |
| AU (2) | AU2012308212A1 (fr) |
| CA (1) | CA2855781A1 (fr) |
| HK (1) | HK1200359A1 (fr) |
| WO (1) | WO2013040564A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245313B2 (en) | 2014-10-24 | 2019-04-02 | Versitech Limited | DNA motif compounds and methods for inducing specific antibodies and cellular immunity |
| CN111153996B (zh) * | 2020-01-10 | 2021-12-14 | 苏州睿瀛生物技术有限公司 | G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8091694A (en) * | 1993-10-26 | 1995-05-22 | United Biomedical Inc. | Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics |
| AU8087994A (en) * | 1993-10-26 | 1995-05-22 | Syntello Inc. | Inhibition of hiv mucosal infection |
| US6441140B1 (en) * | 1998-09-04 | 2002-08-27 | Cell Signaling Technology, Inc. | Production of motif-specific and context-independent antibodies using peptide libraries as antigens |
| US9289487B2 (en) * | 1999-09-14 | 2016-03-22 | Antigen Express, Inc. | II-key/antigenic epitope hybrid peptide vaccines |
| FR2809402A1 (fr) * | 2000-05-26 | 2001-11-30 | Dev Des Antigenes Combinatoire | Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c |
| EP1725099A4 (fr) * | 2004-02-02 | 2009-08-19 | Mixture Sciences Inc | Melanges de peptides a activite immunomodulatrice |
| CA2701948A1 (fr) * | 2007-10-09 | 2009-04-16 | Technologie Integrale Ltd. | Vaccin preventif contre vih a base d'anticorps specifique de vih |
-
2012
- 2012-09-17 EP EP12832007.4A patent/EP2755687A4/fr not_active Withdrawn
- 2012-09-17 WO PCT/US2012/055771 patent/WO2013040564A2/fr active Application Filing
- 2012-09-17 CA CA2855781A patent/CA2855781A1/fr not_active Abandoned
- 2012-09-17 AU AU2012308212A patent/AU2012308212A1/en not_active Abandoned
- 2012-09-17 JP JP2014530928A patent/JP2014527085A/ja active Pending
- 2012-09-17 CN CN201280045106.2A patent/CN104039350B/zh not_active Expired - Fee Related
-
2015
- 2015-01-30 HK HK15101049.2A patent/HK1200359A1/xx unknown
-
2017
- 2017-04-18 JP JP2017082368A patent/JP2017141291A/ja active Pending
- 2017-10-24 AU AU2017251715A patent/AU2017251715A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Claudia Charles-Niño等.Variable epitope libraries:New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1 neutralizing antibody response.《Vaccine》.2011,第29卷(第32期),5313. |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013040564A2 (fr) | 2013-03-21 |
| JP2017141291A (ja) | 2017-08-17 |
| JP2014527085A (ja) | 2014-10-09 |
| WO2013040564A3 (fr) | 2013-06-27 |
| AU2017251715A1 (en) | 2017-11-09 |
| CN104039350A (zh) | 2014-09-10 |
| HK1200359A1 (en) | 2015-08-07 |
| CA2855781A1 (fr) | 2013-03-21 |
| AU2012308212A1 (en) | 2014-03-27 |
| EP2755687A2 (fr) | 2014-07-23 |
| EP2755687A4 (fr) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moore et al. | Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans | |
| Gorny et al. | Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades | |
| Shen et al. | In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth | |
| Sather et al. | Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects | |
| Pantophlet et al. | Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis | |
| Laman et al. | Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain | |
| JPH02160800A (ja) | ヒト免疫不全ウイルス（ＨＩＶ）ｅｎｖ‐コードペプチド | |
| US5459060A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) | |
| US6008044A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC) | |
| Dosenovic et al. | Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization | |
| CA2135630C (fr) | Epitopes de proteines de vih immunologiquement homologues aux proteines de hla | |
| CN104039350B (zh) | 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导 | |
| RU2603262C2 (ru) | Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1 | |
| US11267872B2 (en) | Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits | |
| Binley | Specificities of broadly neutralizing anti-HIV-1 sera | |
| Cham et al. | Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity | |
| Gao et al. | Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins | |
| Burioni et al. | Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site | |
| EP0370090B1 (fr) | Immunogenes et peptides biologiquement actifs derives de sequences partagees d'antigenes et d'anticorps anti-idiotypiques ou d'anticorps specifiques contre des recepteurs cellulaires des antigenes | |
| Chiang et al. | Characterization of a monoclonal antibody specific to the Gag protein of porcine endogenous retrovirus and its application in detecting the virus infection | |
| Vella et al. | A molecular and serologic study of the envelope gene of the British isolate: HIV-1 GB8 | |
| US10660951B2 (en) | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof | |
| Song et al. | Epitope Specificity of Cross‐Clade Neutralizing Sera from Chinese HIV‐1‐Positive Individuals | |
| Sellhorn et al. | JVI Accepts, published online ahead of print on 26 October 2011 | |
| TERSMETTE et al. | Variant-Specific Monoclonal and Group-Specific Polyclonal Human Immunodeficiency Virus Type 1 Neutralizing Antibodies Raised with Synthetic Peptides from the gpl20 Third Variable Domain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1200359 Country of ref document: HK |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160622 Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215125 Xinghu Street No. 218 building B2 room 513 Applicant after: Y-CLONE MEDICAL SCIENCE Co.,Ltd. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215125 Xinghu Street No. 218 building B2 room 513 Applicant before: Suzhou Naao New Material Technology Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1200359 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190705 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |